• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Recombinant human C1 esterase inhibitor as prophylactic treatment in idiopathic non-histaminergic angioedema.

作者信息

Alizadeh Aghdam Mehran, Hofman Zonne L M, Meertens Michelle, Lebens Ans, Hack C Erik, Knulst André C, Maas Coen, Röckmann Heike

机构信息

Department of Dermatology/Allergology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.

Center for Translational Immunology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.

出版信息

Allergy. 2022 Dec;77(12):3673-3676. doi: 10.1111/all.15437. Epub 2022 Jul 22.

DOI:10.1111/all.15437
PMID:35837765
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10084080/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0aa5/10084080/32438cad7b56/ALL-77-3673-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0aa5/10084080/32438cad7b56/ALL-77-3673-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0aa5/10084080/32438cad7b56/ALL-77-3673-g001.jpg

相似文献

1
Recombinant human C1 esterase inhibitor as prophylactic treatment in idiopathic non-histaminergic angioedema.重组人C1酯酶抑制剂作为特发性非组胺能性血管性水肿的预防性治疗。
Allergy. 2022 Dec;77(12):3673-3676. doi: 10.1111/all.15437. Epub 2022 Jul 22.
2
Recombinant human C1 esterase inhibitor as short-term prophylaxis in patients with hereditary angioedema.重组人C1酯酶抑制剂用于遗传性血管性水肿患者的短期预防。
J Allergy Clin Immunol Pract. 2020 Feb;8(2):799-802. doi: 10.1016/j.jaip.2019.08.011. Epub 2019 Aug 19.
3
[Hereditary angioedema due to C1-esterase inhibitor deficiency : novel approaches].[C1酯酶抑制剂缺乏所致遗传性血管性水肿：新方法]
Rev Med Suisse. 2020 Apr 8;16(689):675-678.
4
Efficacy of lanadelumab in acquired angioedema with C1-inhibitor deficiency.拉那度单抗治疗C1抑制剂缺乏所致获得性血管性水肿的疗效
J Allergy Clin Immunol Pract. 2021 Jun;9(6):2490-2491. doi: 10.1016/j.jaip.2021.01.040. Epub 2021 Feb 6.
5
Efficacy of lanadelumab in angioedema due to acquired C1 inhibitor deficiency.拉那度单抗治疗获得性C1抑制物缺乏所致血管性水肿的疗效。
J Allergy Clin Immunol Pract. 2023 Mar;11(3):963-965.e1. doi: 10.1016/j.jaip.2022.10.041. Epub 2022 Nov 13.
6
Recombinant human C1 esterase inhibitor for the treatment of hereditary angioedema due to C1 inhibitor deficiency (C1-INH-HAE).重组人C1酯酶抑制剂用于治疗因C1抑制剂缺乏所致的遗传性血管性水肿（C1-INH-HAE）。
Expert Rev Clin Immunol. 2015 Mar;11(3):319-27. doi: 10.1586/1744666X.2015.1012502. Epub 2015 Feb 10.
7
Novelties in the Diagnosis and Treatment of Angioedema.血管性水肿的诊断和治疗新进展。
J Investig Allergol Clin Immunol. 2016;26(4):212-21; quiz two pages after page 221. doi: 10.18176/jiaci.0087.
8
[Administration of conestat alfa, human C1 esterase inhibitor and icatibant in the treatment of acute angioedema attacks in adults with hereditary angioedema due to C1 esterase inhibitor deficiency. Treatment comparison based on systematic review results].[注射用重组人C1酯酶抑制剂（conestat alfa）、人C1酯酶抑制剂和依卡替班治疗C1酯酶抑制剂缺乏所致遗传性血管性水肿成年患者急性血管性水肿发作的疗效比较。基于系统评价结果的治疗比较]
Pneumonol Alergol Pol. 2013;81(2):95-104.
9
Nanofiltrated C1-esterase-inhibitor in the prophylactic treatment of bradykinin-mediated angioedema.纳米过滤的C1酯酶抑制剂在缓激肽介导的血管性水肿预防性治疗中的应用
Transfusion. 2016 May;56(5):1022-9. doi: 10.1111/trf.13462. Epub 2016 Jan 12.
10
A case of normal C1 esterase inhibitor hereditary angioedema successfully treated with berotralstat.1例用贝罗他司他成功治疗的正常C1酯酶抑制剂遗传性血管性水肿病例。
Ann Allergy Asthma Immunol. 2022 Apr;128(4):462-463. doi: 10.1016/j.anai.2022.01.014. Epub 2022 Jan 19.

本文引用的文献

1
The international WAO/EAACI guideline for the management of hereditary angioedema-The 2021 revision and update.《遗传性血管性水肿管理的国际 WAO/EAACI 指南-2021 年修订版》。
Allergy. 2022 Jul;77(7):1961-1990. doi: 10.1111/all.15214. Epub 2022 Feb 3.
2
Impaired control of the contact system in hereditary angioedema with normal C1-inhibitor.C1抑制因子正常的遗传性血管性水肿中接触系统的控制受损。
Allergy. 2020 Jun;75(6):1394-1403. doi: 10.1111/all.14160. Epub 2020 Feb 6.
3
Hereditary angioedema cosegregating with a novel kininogen 1 gene mutation changing the N-terminal cleavage site of bradykinin.
遗传性血管性水肿与一种新型激肽原1基因突变共分离，该突变改变了缓激肽的N端切割位点。
Allergy. 2019 Dec;74(12):2479-2481. doi: 10.1111/all.13869. Epub 2019 Jun 7.
4
Recombinant human C1 esterase inhibitor for prophylaxis of hereditary angio-oedema: a phase 2, multicentre, randomised, double-blind, placebo-controlled crossover trial.重组人 C1 酯酶抑制剂预防遗传性血管性水肿：一项 2 期、多中心、随机、双盲、安慰剂对照交叉试验。
Lancet. 2017 Sep 30;390(10102):1595-1602. doi: 10.1016/S0140-6736(17)31963-3. Epub 2017 Jul 25.
5
Prophylactic treatment with plasma-derived C1 inhibitor in idiopathic non-histaminergic angioedema.使用血浆源性C1抑制剂对特发性非组胺能性血管性水肿进行预防性治疗。
Pediatr Allergy Immunol. 2016 Sep;27(6):658-9. doi: 10.1111/pai.12592. Epub 2016 Jun 21.
6
Current treatment options for idiopathic angioedema.特发性血管性水肿的当前治疗选择。
Ann Allergy Asthma Immunol. 2015 Nov;115(5):429-33. doi: 10.1016/j.anai.2015.07.023. Epub 2015 Sep 1.
7
Idiopathic nonhistaminergic angioedema successfully treated with ecallantide, icatibant, and C1 esterase inhibitor replacement.用依卡奈肽、艾替班特和C1酯酶抑制剂替代疗法成功治疗特发性非组胺能性血管性水肿。
J Allergy Clin Immunol Pract. 2014 Nov-Dec;2(6):818-9. doi: 10.1016/j.jaip.2014.05.006. Epub 2014 Jul 3.
8
Plasma contact system activation drives anaphylaxis in severe mast cell-mediated allergic reactions.血浆接触系统激活导致严重肥大细胞介导的过敏反应中的过敏反应。
J Allergy Clin Immunol. 2015 Apr;135(4):1031-1043.e6. doi: 10.1016/j.jaci.2014.07.057. Epub 2014 Sep 18.
9
Classification, diagnosis, and approach to treatment for angioedema: consensus report from the Hereditary Angioedema International Working Group.血管性水肿的分类、诊断和治疗方法：遗传性血管性水肿国际工作组的共识报告。
Allergy. 2014 May;69(5):602-16. doi: 10.1111/all.12380. Epub 2014 Mar 27.
10
Development, validation, and initial results of the Angioedema Activity Score.血管性水肿活动评分的制定、验证和初步结果。
Allergy. 2013 Sep;68(9):1185-92. doi: 10.1111/all.12209. Epub 2013 Aug 6.